Chunyu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunyu Liu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bo Zhang
Gastric Cancer Center, West China Hospital, Sichuan University, China
2 shared publications - Chaoyong Shen
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publications - Mingchun Mu
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
2 shared publications - Xiaonan Yin
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publications - Zhaolun Cai
Department of General Surgery; West China Hospital, Sichuan University; Chengdu China
2 shared publications - Zhiyuan Jiang
Plastic Surgeon, Department of Plastic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China.
2 shared publications
Latest Publications
- Open Access
- 6 December 2021
- Published by Springer Nature in Systematic Reviews
- Vol. 10 (1) , 1-5
Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update
Background: There are limited data on the clinical benefits of adding surgical resection in patients with recurrent or metastatic gastrointestinal stromal tumors (GISTs). This protocol outlines the planned scope and methods for a systematic review and meta-analysis update that will compare the clinical outcomes of surgical resection combined with tyrosine kinase inhibitor (TKI) with TKI treatment alone in patients with recurrent or metastatic GISTs. Methods: This review will update a previously published systematic review by our team. This protocol is presented in accordance with the PRISMA-P guideline. PubMed, Embase, and Cochrane Central Register of Controlled Trials will be systematically searched and supplemented by a secondary screening of the references of all included studies. We will include randomized controlled trials (RCTs) and non-randomized studies (NRS) in this review update. The outcomes evaluated will be overall survival and progression-free survival. Two reviewers will independently screen and select studies, extract data from the included studies, and assess the risk of bias of the included studies. Data extracted from RCTs and NRS will be analysed and reported separately. Preplanned subgroup analyses and sensitivity analyses are detailed within this protocol. The strength of the body of evidence will be assessed using GRADE. Discussion: This systematic review and meta-analysis update will provide a current assessment of the evidence for the role of surgery in patients with recurrent or metastatic advanced GISTs. These findings will be used by the Chinese Society of Clinical Oncology (CSCO) GIST guideline recommendations on surgical treatment for recurrent or metastatic advanced GIST patients in China. Systematic review registration: This protocol was prospectively registered in the Open Science Framework Registry (https://osf.io/xus7m).
- 6 December 2021
- Published by Springer Nature in Systematic Reviews
- Vol. 10 (1) , 1-5
Open AccessSurgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update
Background: There are limited data on the clinical benefits of adding surgical resection in patients with recurrent or metastatic gastrointestinal stromal tumors (GISTs). This protocol outlines the planned scope and methods for a systematic review and meta-analysis update that will compare the clinical outcomes of surgical resection combined with tyrosine kinase inhibitor (TKI) with TKI treatment alone in patients with recurrent or metastatic GISTs. Methods: This review will update a previously published systematic review by our team. This protocol is presented in accordance with the PRISMA-P guideline. PubMed, Embase, and Cochrane Central Register of Controlled Trials will be systematically searched and supplemented by a secondary screening of the references of all included studies. We will include randomized controlled trials (RCTs) and non-randomized studies (NRS) in this review update. The outcomes evaluated will be overall survival and progression-free survival. Two reviewers will independently screen and select studies, extract data from the included studies, and assess the risk of bias of the included studies. Data extracted from RCTs and NRS will be analysed and reported separately. Preplanned subgroup analyses and sensitivity analyses are detailed within this protocol. The strength of the body of evidence will be assessed using GRADE. Discussion: This systematic review and meta-analysis update will provide a current assessment of the evidence for the role of surgery in patients with recurrent or metastatic advanced GISTs. These findings will be used by the Chinese Society of Clinical Oncology (CSCO) GIST guideline recommendations on surgical treatment for recurrent or metastatic advanced GIST patients in China. Systematic review registration: This protocol was prospectively registered in the Open Science Framework Registry (https://osf.io/xus7m).
- 1 October 2021
- Published by Elsevier in Pharmacological Research
- Vol. 172, 105808
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis
- 1 October 2021
- Published by Elsevier in Pharmacological Research
- Vol. 172, 105808
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis